#long-acting injectables

ViiV Cabenuva injectable cabotegravir rilpivirine

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

POZ Focus - Different Treatments for Different Populations

This issue explores the latest choices in HIV regimens for various groups, including youth and older people.

Long-Acting Injectables and Older People

Here are considerations for long-term survivors thinking about switching HIV treatments.

Long-Acting Injectables and Younger People

Under 30? Here’s what to consider if you’re thinking about switching HIV treatments.

Making a Different Choice

Switching to a long-acting injectable was right on time for these three people living with HIV.

Treatment: Twice-Yearly

Lenacapavir, a twice-yearly injectable, suppresses viral load in people with highly resistant virus.

Prevention: Long-Acting PrEP

Long-acting injections given every two months could soon offer a new option for HIV pre-exposure prophylaxis.

Long-Acting Injectable PrEP Could Be Approved Early Next Year

Injections of cabotegravir given once every two months may work even better than daily pills for HIV prevention.

Treatment: Cabenuva Preferred

People who used long-acting Cabenuva preferred the injections over their previous daily oral regimen.

Injectable Cabotegravir PrEP Bests Daily Truvada for Gay Men and Trans Women

Twice monthly injections for HIV prevention could be approved early next year.

A Change of Pace

Switching HIV treatments from a daily pill to a monthly injectable has given Mike Hellman more freedom outdoors.

Picking an HIV Treatment for You

From daily pills to long-acting injectables, there are many HIV regimens to consider.

Tips for Picking Your HIV Treatment

Selecting an HIV regimen depends on doing your homework.

Twice-Yearly Lenacapavir Works Well for People with Highly Resistant HIV

The novel HIV capsid inhibitor also shows promise for previously untreated people.

Untangling Why Young People Don’t Take PrEP

Awareness of the HIV prevention pills don’t match their use.

People With HIV Are Highly Satisfied With Cabenuva

Injections given every month or every other month were preferred over daily pills.

Sharing Her Journey of Empowerment

Shirley Selvage has built a healthy partnership with her providers.

#long-acting injectables

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

POZ Focus - Different Treatments for Different Populations

Long-Acting Injectables and Older People

Long-Acting Injectables and Younger People

Making a Different Choice

Treatment: Twice-Yearly

Prevention: Long-Acting PrEP

Long-Acting Injectable PrEP Could Be Approved Early Next Year

Treatment: Cabenuva Preferred

Injectable Cabotegravir PrEP Bests Daily Truvada for Gay Men and Trans Women

A Change of Pace

Picking an HIV Treatment for You

Tips for Picking Your HIV Treatment

Twice-Yearly Lenacapavir Works Well for People with Highly Resistant HIV

Untangling Why Young People Don’t Take PrEP

People With HIV Are Highly Satisfied With Cabenuva

Sharing Her Journey of Empowerment

Science News

Ask POZ